AMAG Pharma (AMAG) Posts Wider Q2 Loss

AMAG Pharma (NASDAQ: AMAG) reported Q2 EPS of ($3.57), which may not compare to the analyst estimate of ($0.57). Revenue for the quarter came in at $78.1 million versus the consensus estimate of $91.77 million.

“We are pleased to report both year-over-year and sequential revenue and market share growth in the quarter for each of our key commercial products - Makena subcutaneous (SC) auto-injector, Feraheme and Intrarosa. This strong, consistent execution by our commercial team positions us well for next month's launch of Vyleesi, our fourth commercial product,” said William Heiden, AMAG’s president and chief executive officer. “Despite the strong commercial success of our promoted products, we have lowered our 2019 financial guidance to reflect the impact of Makena intramuscular (IM) supply issues and our changed expectations of milestone payments due to us from a development partner related to ciraparantag.”

For earnings history and earnings-related data on AMAG Pharma (AMAG) click here.

You May Also Be Interested In

• HubSpot (HUBS) Tops Q3 EPS by 54c; offers guidance
• Radient Pharmaceuticals (RPC) Misses Q3 EPS by 1c
• Cirrus Logic, Inc. (CRUS) Tops Q2 EPS by 27c; offers guidance